2013
DOI: 10.2217/clp.13.31
|View full text |Cite
|
Sign up to set email alerts
|

Lipoxins, resolvins, protectins, maresins and nitrolipids, and their clinical implications with specific reference to cancer: part I

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
35
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 30 publications
(37 citation statements)
references
References 179 publications
2
35
0
Order By: Relevance
“…The relative proportions of LCPUFAs in cell membranes, as well as cell type, are the primary factors that regulate the formation of some of these bioactive lipid metabolites. It is likely that eSS rats treated with ω-3 LCPUFAs may lead to the formation of some of these anti-inflammatory metabolites such as lipoxins, resolvins and protectins [28, 29]. This assumption is supported by our recent studies that showed that lipoxin A4, an anti-inflammatory product formed from AA has anti-diabetic actions in chemical-induced diabetic animal models [27].…”
Section: Resultsmentioning
confidence: 95%
See 2 more Smart Citations
“…The relative proportions of LCPUFAs in cell membranes, as well as cell type, are the primary factors that regulate the formation of some of these bioactive lipid metabolites. It is likely that eSS rats treated with ω-3 LCPUFAs may lead to the formation of some of these anti-inflammatory metabolites such as lipoxins, resolvins and protectins [28, 29]. This assumption is supported by our recent studies that showed that lipoxin A4, an anti-inflammatory product formed from AA has anti-diabetic actions in chemical-induced diabetic animal models [27].…”
Section: Resultsmentioning
confidence: 95%
“…The LCPUFAs derived from LA and ALA serve as precursors to several biologically active molecules such as prostaglandins (PGs), leukotrienes (LTs), thromboxanes (TXs), lipoxins (LXs), resolvins, protectins and endocannabinoids. These metabolites have potent pro-inflammatory or anti-inflammatory actions [28, 29]. The relative proportions of LCPUFAs in cell membranes, as well as cell type, are the primary factors that regulate the formation of some of these bioactive lipid metabolites.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Despite these impressive results and arguments, it is noteworthy that the exact mechanism(s) by which EPA and DHA can prevent AAA induced by angiotensin-II infusion remains unclear. It is not clear whether EPA and DHA themselves can bring about this beneficial action or they need to be converted to their respective anti-inflammatory compounds such as resolvins and protectins and maresins [3][4][5][6] (resolvins E1, E2 and E3 are formed from EPA; while resolvins D1, D2, D3 and D4, protectins and maresins are formed from DHA, see Figures 1 and 2). Another important information that should have been generated is to know how much of the administered EPA and DHA were incorporated at the site of AAA and whether there is any correlation between the amount of EPA and DHA present and AAA.…”
Section: Pufas and Their Metabolites Angiotensin-ii Aa And Aaamentioning
confidence: 99%
“…Resolvins/protectins/maresins are not only antiinflammatory, [3][4][5][6] but also possess anti-fibrotic actions [15] and inhibit the proliferation of fibroblasts [15] and thus, angiotensin-II-induced AAA could be prevented. Since angiotensin-II has pro-inflammatory actions [11][12][13] and resolvins, protectins and maresins are anti-inflammatory in nature, this may explain the ability of EPA and DHA to prevent AAA.…”
Section: Pufas and Their Metabolites Angiotensin-ii Aa And Aaamentioning
confidence: 99%